Form 4: Pacira BioSciences Chief Medical Officer Reports Stock Sale and Acquisition

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports selling shares and acquiring restricted stock units.

Summary

• On June 11, 2024, Jonathan Slonin, the Chief Medical Officer of Pacira BioSciences, sold 5,012 shares of common stock at a price of $28.57 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• On June 12, 2024, Slonin acquired 54,300 restricted stock units (RSUs) at a price of $0.
• These RSUs vest in four equal annual installments starting on June 3, 2025, contingent upon continued service with Pacira BioSciences.
• Following these transactions, Slonin beneficially owns 98,869.475 shares of Pacira BioSciences common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document primarily reports transactions without expressing a clear positive or negative outlook. The sale is under a pre-arranged plan, and the acquisition of RSUs is a standard compensation practice.

Positives

• The acquisition of restricted stock units indicates a long-term incentive for the Chief Medical Officer to remain with the company.

Negatives

• The sale of shares, even under a 10b5-1 plan, could be interpreted negatively by some investors.

Risks

• The vesting of the restricted stock units is contingent upon continued service, creating a potential risk if the executive leaves the company before the vesting dates.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock units suggests a multi-year commitment from the executive.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often related to compensation packages and personal financial planning. The use of 10b5-1 plans is a standard practice to avoid insider trading accusations.

Comparison to Industry Standards

• Executive compensation packages in the biopharmaceutical industry often include a mix of salary, stock options, and restricted stock units.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies to align executive interests with shareholder value.
• The vesting schedules and terms of these equity grants are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although it is likely mitigated by the pre-arranged trading plan.
• The RSU grant incentivizes the Chief Medical Officer, potentially benefiting shareholders through his continued contributions to the company.

Key Dates